Stock Performance and Market Context
On 17 June 2026, Fredun Pharmaceuticals Ltd’s stock price surged by 4.59% during the trading session, outperforming the Sensex which recorded a modest 0.18% gain. The stock touched an intraday high of ₹2,616, representing a 3.29% increase on the day, and closed just 0.23% shy of its 52-week high of ₹2,620. This marks the culmination of a four-day consecutive gain period, during which the stock delivered a remarkable 16.2% return.
Over various time horizons, Fredun Pharmaceuticals has consistently outperformed benchmark indices. Its one-year return stands at an impressive 216.49%, vastly exceeding the Sensex’s decline of 5.69% over the same period. Year-to-date, the stock has appreciated by 67.84%, while the Sensex has fallen by 9.71%. Longer-term performance also highlights the company’s strength, with a five-year return of 523.88% compared to the Sensex’s 47.06%, and a staggering ten-year return of 13,145% against the Sensex’s 188.99%.
Technical Indicators and Trend Analysis
The technical outlook for Fredun Pharmaceuticals remains bullish. The stock is trading above all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling strong upward momentum. Key technical indicators such as MACD, Bollinger Bands, and KST are aligned with a bullish trend on both weekly and monthly charts. The current trend was confirmed as bullish on 9 April 2026 at a price level of ₹1,830, and has since maintained this positive trajectory.
Support levels are well established, with the immediate support at ₹791, the 52-week low, providing a solid base. Resistance levels include the 20-day moving average at ₹2,378 and the 52-week high at ₹2,620, which the stock has now surpassed intraday. Delivery volumes have also shown a significant increase, with a 1-day delivery change of 304.11% compared to the 5-day average, indicating strong investor participation in recent sessions.
Financial Performance and Growth Metrics
Fredun Pharmaceuticals has demonstrated healthy financial growth, with net sales growing at an annual rate of 36.42% over the past five years. Operating profit has expanded even more rapidly, at a rate of 59.04%, reflecting improving operational efficiency. The company has reported positive results for eight consecutive quarters, with the latest quarterly Profit Before Tax (excluding other income) reaching ₹11.25 crores, a growth of 54.96% year-on-year.
Quarterly Profit After Tax (PAT) hit a record high of ₹10.78 crores, underscoring the company’s profitability. The debt-equity ratio for the half-year period stands at a conservative 0.80 times, indicating a manageable leverage position. Return on Capital Employed (ROCE) is attractive at 19.9%, supported by an enterprise value to capital employed ratio of 3.6, suggesting efficient capital utilisation.
Valuation and Quality Assessment
At a price-to-earnings (P/E) ratio of 37 times (TTM), Fredun Pharmaceuticals is trading at a valuation that reflects its growth prospects, supported by a PEG ratio of 0.65, which indicates the stock is reasonably valued relative to its earnings growth. Other valuation multiples include a price-to-book value of 5.01 times and an EV/EBITDA of 16.38 times.
The company’s dividend yield is modest at 0.02%, with a recent dividend payout of ₹0.70 per share and a payout ratio of 2.11%, consistent with its focus on reinvestment and growth. Quality metrics classify Fredun Pharmaceuticals as an average quality company based on long-term financial performance, with excellent growth but below-average capital structure metrics. The company maintains a low promoter share pledge at 0.0%, and promoters have increased their stake by 1.11% in the previous quarter, now holding 44.17% of the equity, signalling strong promoter confidence.
Long-Term Market Outperformance
Fredun Pharmaceuticals has consistently outperformed the broader market and its sector peers. Its three-year return of 196.41% surpasses the BSE500 index’s 21.39% gain, while its one-year and three-month returns also significantly exceed benchmark indices. This sustained outperformance is supported by strong fundamentals, improving profitability, and a positive technical trend.
The company’s ability to generate robust sales growth alongside expanding operating margins has been a key driver of its stock price appreciation. Despite moderate leverage and interest coverage ratios, the firm’s financial discipline and steady earnings growth have contributed to its rising market valuation.
Summary of Key Financial and Market Metrics as of 17 June 2026
Price: ₹2,649.00
Market Cap Grade: Micro-cap
Mojo Score: 71.0 (Upgraded from Hold to Buy on 30 May 2026)
52-Week Range: ₹791.00 – ₹2,620.00
P/E Ratio (TTM): 37x
PEG Ratio: 0.65x
ROCE: 19.9%
Debt-Equity Ratio (HY): 0.80 times
Quarterly PAT: ₹10.78 crores (highest recorded)
Consecutive Positive Quarters: 8
Promoter Holding: 44.17% (increased by 1.11%)
Fredun Pharmaceuticals Ltd’s ascent to an all-time high price reflects a combination of strong financial results, positive technical momentum, and growing promoter confidence. The company’s consistent growth in sales and profits, coupled with disciplined capital management, has underpinned this milestone achievement in the competitive Pharmaceuticals & Biotechnology sector.
